EU panel backs approval of GSK's cancer drugs Tafinlar and Tyverb

07/2/2013 | Pharmaceutical Business Review Online

The European Medicines Agency's Committee for Medicinal Products for Human Use endorsed the approval of GlaxoSmithKline's Tafinlar, or dabrafenib, as a treatment for unresectable or metastatic melanoma in patients with the BRAF V600 mutation. GSK's Tyverb, or lapatinib, along with trastuzumab, was also recommended for approval as combination therapy for certain breast cancer patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC